title: Platelet-activating factor and antagonists modulate DNA synthesis in human bone marrow stromal cell cultures.
abstract: Platelet-activating factor (PAF) is present in the human bone marrow. We have investigated the effect of PAF and antagonists (BN 52,021 and CV 3988) on the growth of human marrow stromal cells. PAF (1 microM) stimulates and PAF antagonists (0.1-1 microM) inhibit [3H]thymidine incorporation in cells grown in 5% serum. The catabolism of PAF by stromal cells was inhibited by CV 3988 suggesting the presence of specific PAF receptor on cells. PAF and antagonists (0.1 nM-10 microM) had no effect on cells cultured in high serum concentration (20%) or in low serum concentration (1%) with 0.5 ng/ml of basic fibroblast growth factor (bFGF). This study indicates for the first time that PAF modulates the serum-induced but not the bFGF-induced growth of marrow stromal cells. The interactions between PAF and stromal cells during inflammatory marrow events such as myelofibrosis deserve to be assessed.
authors.affiliation: Laboratoire d'Hématologie Expérimentale, Faculté de Médecine, Limoges, France.
authors.forename: F
authors.initials: F
authors.lastname: Rougier
authors.forename: F
authors.initials: F
authors.lastname: Dupuis
authors.forename: E
authors.initials: E
authors.lastname: Cornu
authors.forename: C
authors.initials: C
authors.lastname: Dulery
authors.forename: V
authors.initials: V
authors.lastname: Praloran
authors.forename: Y
authors.initials: Y
authors.lastname: Denizot
mesh_terms: D043203:1-Alkyl-2-acetylglycerophosphocholine Esterase; D001769:Blood; D001853:Bone Marrow / Q000187:drug effects* / Q000378:metabolism; D001854:Bone Marrow Cells; D002478:Cells, Cultured; D003470:Culture Media; D004261:DNA Replication / Q000187:drug effects*; D004224:Diterpenes; D005343:Fibrinolytic Agents / Q000494:pharmacology; D016222:Fibroblast Growth Factor 2 / Q000494:pharmacology; D046934:Ginkgolides; D006801:Humans; D007783:Lactones / Q000494:pharmacology; D010741:Phospholipases A / Q000378:metabolism; D010742:Phospholipid Ethers / Q000494:pharmacology; D010972:Platelet Activating Factor / Q000037:antagonists & inhibitors / Q000378:metabolism / Q000494:pharmacology*; D010975:Platelet Aggregation Inhibitors / Q000494:pharmacology*; D010980:Platelet Membrane Glycoproteins / Q000037:antagonists & inhibitors / Q000378:metabolism; D055728:Primary Myelofibrosis / Q000378:metabolism; D011956:Receptors, Cell Surface; D043562:Receptors, G-Protein-Coupled; D017154:Stromal Cells / Q000187:drug effects* / Q000378:metabolism; D013936:Thymidine / Q000378:metabolism
chemical_list: D003470:Culture Media; D004224:Diterpenes; D005343:Fibrinolytic Agents; D046934:Ginkgolides; D007783:Lactones; D010742:Phospholipid Ethers; D010972:Platelet Activating Factor; D010975:Platelet Aggregation Inhibitors; D010980:Platelet Membrane Glycoproteins; D011956:Receptors, Cell Surface; D043562:Receptors, G-Protein-Coupled; C039351:platelet activating factor receptor; D016222:Fibroblast Growth Factor 2; C037913:CV 3988; C045856:ginkgolide B; D010741:Phospholipases A; D043203:1-Alkyl-2-acetylglycerophosphocholine Esterase; D013936:Thymidine